Literature DB >> 11413323

Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

O Scharf1, H Golding, L R King, N Eller, D Frazier, B Golding, D E Scott.   

Abstract

Passive antibody prophylaxis against human immunodeficiency virus type 1 (HIV-1) has been accomplished in primates, suggesting that this strategy may prove useful in humans. While antibody specificity is crucial for neutralization, other antibody characteristics, such as subclass, have not been explored. Our objective was to compare the efficiencies of immunoglobulin G (IgG) subclasses from polyclonal human HIV immune globulin (HIVIG) in the neutralization of HIV-1 strains differing in coreceptor tropism. IgG1, IgG2, and IgG3 were enriched from HIVIG by using protein A-Sepharose. All three subclasses bound major HIV-1 proteins, as shown by Western blot assay and enzyme-linked immunosorbent assay. In HIV-1 fusion assays using X4, R5, or X4R5 envelope-expressing effector cells, IgG3 more efficiently blocked fusion. In neutralization assays with cell-free viruses using X4 (LAI, IIIB), R5 (BaL), and X4R5 (DH123), a similar hierarchy of neutralization was found: IgG3 > IgG1 > IgG2. IgG3 has a longer, more flexible hinge region than the other subclasses. To test whether this is important, IgG1 and IgG3 were digested with pepsin to generate F(ab')(2) fragments or with papain to generate Fab fragments. IgG3 F(ab')(2) fragments were still more efficient in neutralization than F(ab')(2) of IgG1. However, Fab fragments of IgG3 and IgG1 demonstrated equivalent neutralization capacities and the IgG3 advantage was lost. These results suggest that the IgG3 hinge region confers enhanced HIV-neutralizing ability. Enrichment and stabilization of IgG3 may therefore lead to improved HIVIG preparations. The results of this study have implications for the improvement of passive immunization with polyclonal or monoclonal antibodies and suggest that HIV-1 vaccines which induce high-titer IgG3 responses could be advantageous.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413323      PMCID: PMC114379          DOI: 10.1128/JVI.75.14.6558-6565.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Immune globulins.

Authors:  J S Finlayson
Journal:  Semin Thromb Hemost       Date:  1979       Impact factor: 4.180

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Papain sensitivity of heavy chain sub-classes in normal human IgG and localizaton of antigenic determinants for the sub-classes.

Authors:  G Virella; R M Parkhouse
Journal:  Immunochemistry       Date:  1971-03

5.  IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A.

Authors:  F Skvaril; B Roth-Wicky; S Barandun
Journal:  Vox Sang       Date:  1980       Impact factor: 2.144

6.  Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit.

Authors:  T E Michaelsen; B Frangione; E C Franklin
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

7.  The G4 subclass in IgG fractions prepared by ion-exchange chromatography.

Authors:  F Skvaril; A Morell
Journal:  J Immunol       Date:  1970-05       Impact factor: 5.422

8.  Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).

Authors:  E R Stiehm; C V Fletcher; L M Mofenson; P E Palumbo; M Kang; T Fenton; C V Sapan; W A Meyer; W T Shearer; E Hawkins; M G Fowler; P Bouquin; L Purdue; E M Sloand; G J Nemo; D Wara; Y J Bryson; S E Starr; A Petru; S Burchett
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

9.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

10.  pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose.

Authors:  R C Duhamel; P H Schur; K Brendel; E Meezan
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

View more
  48 in total

Review 1.  Structure and function of immunoglobulins.

Authors:  Harry W Schroeder; Lisa Cavacini
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

2.  Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.

Authors:  Sara Crespillo; Salvador Casares; Pedro L Mateo; Francisco Conejero-Lara
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

3.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

Review 4.  B-cell abnormalities in HIV-1 infection: roles for IgG3 and T-bet.

Authors:  Lela Kardava; Susan Moir
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

5.  Sooty mangabey (Cercocebus torquatus atys) IGHG and IGHA genes.

Authors:  Franco Scinicariello; Feda Masseoud; Lakshmi Jayashankar; Roberta Attanasio
Journal:  Immunogenetics       Date:  2006-10-18       Impact factor: 2.846

6.  Errors in data interpretation from genetic variation of human analytes.

Authors:  Heather L Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Linda Kapp; Jenna N Lebedev; James C Zimring
Journal:  JCI Insight       Date:  2017-07-06

7.  Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.

Authors:  Yvonne Hofmeister; Christina B Planitzer; Maria R Farcet; Wolfgang Teschner; H Arno Butterweck; Alfred Weber; Georg W Holzer; Thomas R Kreil
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

8.  An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques.

Authors:  Rebecca L Powell; Svenja Weiss; Alisa Fox; Xiaomei Liu; Vincenza Itri; Xunqing Jiang; Christina C Luo; David A Spencer; Shilpi Pandey; Tracy Cheever; Deborah H Fuller; Maxim Totrov; Ann J Hessell; Nancy L Haigwood; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

9.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

10.  Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions.

Authors:  Franco Scinicariello; Carrie N Engleman; Lakshmi Jayashankar; Harold M McClure; Roberta Attanasio
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.